Stereotactic radiosurgery recommended for patients with more than three brain metastases
Researchers from The University of Texas MD Anderson Cancer Center have conducted the first randomized clinical trial comparing stereotactic radiosurgery (SRS) to whole brain radiation therapy (WBRT) in patients with four to 15 brain metastases, providing evidence to support the use of SRS in this patient population.
Results from the Phase III trial, led by Jing Li, M.D., Ph.D., associate professor of Radiation Oncology and co-director...
MD Anderson's fifth annual Boot Walk to End Cancer® goes virtual Nov. 7
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov...
Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused...
MD Anderson, UT Austin Announce First Collaborative Projects in United Fight to End Cancer
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is needed to address this devastating disease.
Earlier this year, The University of Texas MD Anderson Cancer Center, UT Austin Oden Institute for Computational Engineering and Sciences, and UT Austin Texas Advanced Computing Center (TACC) launched a new collaboration in Oncological Data and Computational...
MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
MD Anderson earns fifth Magnet designation for nursing excellence
The University of Texas MD Anderson Cancer Center today announced achievement of its fifth consecutive Magnet designation, the highest distinction...
Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD...
Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in patients with large B-cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19...
Study finds cancer mutations accumulate in distinct regions based on structure of genome and mutational causes
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do not accumulate...